SG11201704976VA - Hemiasterlin derivatives for conjugation and therapy - Google Patents
Hemiasterlin derivatives for conjugation and therapyInfo
- Publication number
- SG11201704976VA SG11201704976VA SG11201704976VA SG11201704976VA SG11201704976VA SG 11201704976V A SG11201704976V A SG 11201704976VA SG 11201704976V A SG11201704976V A SG 11201704976VA SG 11201704976V A SG11201704976V A SG 11201704976VA SG 11201704976V A SG11201704976V A SG 11201704976VA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugation
- therapy
- hemiasterlin derivatives
- hemiasterlin
- derivatives
- Prior art date
Links
- KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical class C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 title 1
- 230000021615 conjugation Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110390P | 2015-01-30 | 2015-01-30 | |
| PCT/US2016/015844 WO2016123582A1 (en) | 2015-01-30 | 2016-01-29 | Hemiasterlin derivatives for conjugation and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704976VA true SG11201704976VA (en) | 2017-07-28 |
Family
ID=55398448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704976VA SG11201704976VA (en) | 2015-01-30 | 2016-01-29 | Hemiasterlin derivatives for conjugation and therapy |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10844090B2 (en) |
| EP (2) | EP3250237B1 (en) |
| JP (2) | JP6883518B2 (en) |
| KR (1) | KR102587808B1 (en) |
| CN (2) | CN107428801B (en) |
| AU (1) | AU2016211165B2 (en) |
| CA (1) | CA2971766A1 (en) |
| DK (1) | DK3250237T3 (en) |
| ES (1) | ES2878023T3 (en) |
| HR (1) | HRP20211164T1 (en) |
| HU (1) | HUE055644T2 (en) |
| IL (1) | IL253712B (en) |
| LT (1) | LT3250237T (en) |
| PL (1) | PL3250237T3 (en) |
| PT (1) | PT3250237T (en) |
| SG (1) | SG11201704976VA (en) |
| SI (1) | SI3250237T1 (en) |
| WO (1) | WO2016123582A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201408161RA (en) | 2012-06-08 | 2015-01-29 | Sutro Biopharma Inc | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| ES2658039T3 (en) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use |
| KR101628872B1 (en) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | Compounds comprising self-immolative group |
| WO2017051254A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
| WO2017051249A1 (en) * | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| JP7120765B2 (en) | 2015-11-25 | 2022-08-17 | レゴケム バイオサイエンシズ， インク． | CONJUGATES CONTAINING PEPTIDE GROUPS AND RELATED METHODS |
| KR20180078329A (en) | 2015-11-25 | 2018-07-09 | 주식회사 레고켐 바이오사이언스 | Antibody-drug conjugates comprising branched linkers and methods for their preparation |
| EP3380124B1 (en) | 2015-11-25 | 2024-04-03 | LegoChem Biosciences, Inc. | Conjugates comprising self-immolative groups and methods related thereto |
| KR20180104106A (en) * | 2016-01-27 | 2018-09-19 | 서트로 바이오파마, 인크. | an anti-CD74 antibody conjugate, a composition comprising an anti-CD74 antibody conjugate, and an anti-CD74 antibody conjugate |
| KR20190126314A (en) * | 2017-02-10 | 2019-11-11 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | Trigger Activatable Sugar Conjugates for Cancer-Selective Labeling and Targeting |
| US11654197B2 (en) | 2017-03-29 | 2023-05-23 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
| CA3072153A1 (en) | 2017-08-10 | 2019-02-14 | Sumitomo Dainippon Pharma Co., Ltd. | Antibody-drug conjugates including hemiasterlin derivative |
| CN111051329A (en) * | 2017-08-10 | 2020-04-21 | 大日本住友制药株式会社 | Hamiltrin derivatives and antibody drug complexes thereof |
| US10596270B2 (en) | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
| MX2020011554A (en) | 2018-05-09 | 2020-11-24 | Legochem Biosciences Inc | Compositions and methods related to anti-cd19 antibody drug conjugates. |
| JP2022500454A (en) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | Combination therapy with antifolate receptor antibody conjugate |
| CN113412271A (en) | 2019-02-13 | 2021-09-17 | 大日本住友制药株式会社 | Hamiltrin derivatives having cysteine residue |
| CR20210541A (en) | 2019-03-29 | 2021-12-20 | Medimmune Ltd | Compounds and conjugates thereof |
| US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
| EP3980080A1 (en) * | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
| KR20210028544A (en) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use |
| CN111117966A (en) * | 2020-03-02 | 2020-05-08 | 南通大学 | In-vitro cell culture method using lactic acid |
| IL297329A (en) | 2020-04-22 | 2022-12-01 | Merck Sharp & Dohme Llc | Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer |
| KR20240004659A (en) | 2021-04-30 | 2024-01-11 | 셀진 코포레이션 | Combination therapy using an anti-BCMA antibody-drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
| EP4340876A1 (en) | 2021-05-19 | 2024-03-27 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate combination therapy with bevacizumab |
| WO2023102077A1 (en) | 2021-12-01 | 2023-06-08 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate cancer therapy |
| US20240091365A1 (en) * | 2022-06-27 | 2024-03-21 | Sutro Biopharma, Inc. | Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof |
| US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5661175A (en) | 1995-06-20 | 1997-08-26 | Kashman; Yoel | Hemiasterlin and geodiamolide TA |
| CA2225325A1 (en) | 1997-12-19 | 1999-06-19 | The University Of British Columbia | Hemiasterlin analogs |
| AU2003224644A1 (en) | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| WO2003082268A2 (en) | 2002-03-22 | 2003-10-09 | Eisai Co. Ltd | Hemiasterlin derivatives and uses thereof in the treatment of cancer |
| US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| AU2003275126A1 (en) | 2002-09-20 | 2004-04-08 | Wyeth Holdings Corporation | Hemiasterlin derivatives for treating resistant tumors |
| US7390910B2 (en) | 2003-08-08 | 2008-06-24 | Wyeth | Compounds for treating tumors |
| CN105358174B (en) | 2013-03-15 | 2019-03-15 | 酵活有限公司 | Have cytotoxicity and antimitotic compound and its application method |
| US10675355B2 (en) | 2013-12-27 | 2020-06-09 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
-
2016
- 2016-01-29 AU AU2016211165A patent/AU2016211165B2/en active Active
- 2016-01-29 WO PCT/US2016/015844 patent/WO2016123582A1/en active Application Filing
- 2016-01-29 US US15/011,388 patent/US10844090B2/en active Active
- 2016-01-29 PT PT167053875T patent/PT3250237T/en unknown
- 2016-01-29 KR KR1020177023820A patent/KR102587808B1/en active IP Right Grant
- 2016-01-29 EP EP16705387.5A patent/EP3250237B1/en active Active
- 2016-01-29 PL PL16705387T patent/PL3250237T3/en unknown
- 2016-01-29 SG SG11201704976VA patent/SG11201704976VA/en unknown
- 2016-01-29 JP JP2017540065A patent/JP6883518B2/en active Active
- 2016-01-29 DK DK16705387.5T patent/DK3250237T3/en active
- 2016-01-29 CN CN201680007822.XA patent/CN107428801B/en active Active
- 2016-01-29 LT LTEP16705387.5T patent/LT3250237T/en unknown
- 2016-01-29 ES ES16705387T patent/ES2878023T3/en active Active
- 2016-01-29 CN CN202210281131.6A patent/CN114716506A/en active Pending
- 2016-01-29 SI SI201631257T patent/SI3250237T1/en unknown
- 2016-01-29 CA CA2971766A patent/CA2971766A1/en active Pending
- 2016-01-29 HU HUE16705387A patent/HUE055644T2/en unknown
- 2016-01-29 EP EP21175538.4A patent/EP3892305A1/en active Pending
-
2017
- 2017-07-28 IL IL253712A patent/IL253712B/en unknown
-
2020
- 2020-11-02 US US17/087,597 patent/US20210261611A1/en active Pending
- 2020-11-02 US US17/087,594 patent/US11866515B2/en active Active
-
2021
- 2021-05-10 JP JP2021079604A patent/JP2021138706A/en active Pending
- 2021-07-21 HR HRP20211164TT patent/HRP20211164T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210261611A1 (en) | 2021-08-26 |
| KR20170106472A (en) | 2017-09-20 |
| CA2971766A1 (en) | 2016-08-04 |
| HRP20211164T1 (en) | 2021-10-29 |
| HUE055644T2 (en) | 2022-03-28 |
| IL253712B (en) | 2021-12-01 |
| PT3250237T (en) | 2021-06-30 |
| BR112017016122A2 (en) | 2018-04-17 |
| CN107428801B (en) | 2022-12-20 |
| JP2021138706A (en) | 2021-09-16 |
| KR102587808B1 (en) | 2023-10-10 |
| US11866515B2 (en) | 2024-01-09 |
| US20160257709A1 (en) | 2016-09-08 |
| PL3250237T3 (en) | 2021-12-13 |
| EP3892305A1 (en) | 2021-10-13 |
| LT3250237T (en) | 2021-09-27 |
| IL253712A0 (en) | 2017-09-28 |
| AU2016211165A2 (en) | 2019-12-12 |
| DK3250237T3 (en) | 2021-07-26 |
| JP2018508490A (en) | 2018-03-29 |
| CN107428801A (en) | 2017-12-01 |
| AU2016211165A1 (en) | 2017-06-29 |
| AU2016211165B2 (en) | 2021-06-24 |
| US10844090B2 (en) | 2020-11-24 |
| JP6883518B2 (en) | 2021-06-09 |
| ES2878023T3 (en) | 2021-11-18 |
| WO2016123582A1 (en) | 2016-08-04 |
| EP3250237A1 (en) | 2017-12-06 |
| CN114716506A (en) | 2022-07-08 |
| SI3250237T1 (en) | 2021-11-30 |
| US20210198314A1 (en) | 2021-07-01 |
| EP3250237B1 (en) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253712B (en) | Hemiasterlin derivatives for conjugation and therapy | |
| IL271888A (en) | Therapeutic and diagnostic methods for cancer | |
| HK1248773A1 (en) | Therapeutic and diagnostic methods for cancer | |
| HK1250376A1 (en) | Therapeutic and diagnostic methods for cancer | |
| IL265759A (en) | Therapeutic and diagnostic methods for cancer | |
| IL268396A (en) | Diagnostic and therapeutic methods for cancer | |
| IL258931A (en) | Therapeutic compounds and methods | |
| HK1231367A1 (en) | Antibody-drug conjugates, their preparation and their therapeutic use | |
| IL274246A (en) | Diagnostic and therapeutic methods for cancer | |
| IL261422A (en) | Therapeutic and diagnostic methods for cancer | |
| HK1251183A1 (en) | Bioconjugates and uses thereof | |
| IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
| IL273071A (en) | Diagnostic and therapeutic methods for cancer | |
| IL253549B (en) | Antibody-urease conjugates for therapeutic purposes | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| ZA201902689B (en) | Therapeutic protein | |
| IL270011B (en) | Therapeutic compounds and methods | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| EP3143036C0 (en) | Par-1 based therapeutic conjugates and uses thereof | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| IL274866A (en) | Compositions and methods for cancer therapy | |
| GB201700099D0 (en) | Therapeutic method | |
| GB201616715D0 (en) | Therapeutic protein |